Targeting p53, hdm2, and CD19: vaccination and immunologic strategies

Area of Science:

• Immunology
• Oncology
• Genetics

Background:

• Class I MHC-presented self-peptides from elevated self-proteins in malignancies are theoretical targets for CTL-based cancer immunotherapy.
• Low-level expression of these self-proteins in normal tissues can induce self-tolerance, preventing effective anti-tumor immune responses.
• Intrathymic deletion of high-avidity T cells specific for self-MHC-self-peptide complexes limits the repertoire of anti-tumor CTL precursors.

Purpose of the Study:

• To develop a strategy to circumvent self-tolerance and generate human (Hu) HLA-restricted cytotoxic T lymphocytes (CTLs) specific for tumor-associated self-antigens.
• To utilize species differences between human and murine protein sequences in HLA-transgenic (Tg) mouse models.

Main Methods:

• Employing HLA-transgenic (Tg) mice that express human HLA molecules.
• Exploiting differences between human and murine protein sequences to bypass self-tolerance mechanisms.
• Generating and characterizing HLA-restricted CTLs specific for epitopes derived from human tumor-associated self-proteins.

Main Results:

• Demonstrated the feasibility of generating HLA-restricted CTLs specific for human tumor-associated self-epitopes in a mouse model.
• Successfully circumvented natural self-tolerance mechanisms that would otherwise eliminate such T cells.
• Identified potential target antigens like p53, Her-2/neu, hdm2, and CD19 for immunotherapy.

Conclusions:

• HLA-transgenic mouse models offer a viable approach to overcome self-tolerance in cancer immunotherapy.
• This strategy enables the generation of potent anti-tumor CTL responses against naturally occurring self-antigens.
• The findings support the development of novel immunotherapies targeting specific tumor-associated self-proteins.